Category: Laser/Light-based Devices
Biolase steadies itself against a proxy war filed by activist majority shareholder Oracle Partners over alleged manipulation of the board of directors.
Medical lasers maker Biolase is still examining "strategic alternatives" for the company as its slashes about $1.3 million from its payroll and posts continued quarterly losses.
California medtech company Biolase (NSDQ:BIOL) is looking to slim down ahead of a potential acquisition as the company examines its "strategic alternatives."
Lumenis prices its initial public offering at $12 per share, meaning it will raise about 20% less from the IPO; shares gain nearly 9% in 1st trading.
Lumenis Ltd. today priced its initial public offering at $12 per share, 20% under the low end of the prior $15-$17 range set by the Israeli maker of medical lasers.
Lumenis shares, trading under the "LMNS" symbol on the NASDAQ exchange, opened up 4.2% at $12.50 today and were fetching $13.05 apiece as of about 11:20 a.m., up 8.8%.
Syneron Medical has a big week with Q4 earnings that beat estimates, a new chief executive and the $15 million acquisition of New Star Lasers and its CoolTouch aesthetic devices.
Israeli device maker Syneron Medical Ltd. (NSDQ:ELOS) made some major moves this month, announcing a new CEO alongside strong Q4 earnings and signing a deal to acquire New Lasers Inc.
Biolase ties the bow on a $5 million private placement with Oracle Investment Management it plans to use to pay down debt.
Biolase (NSDQ:BIOL) said it closed a $5 million private placement with Oracle Investment Management.
The surgical laser maker sold off a little more than 1.9 million shares for $2.57 each, with the deal closing on Feb. 10. The money is expected to go toward paying down its $4.6 million credit facility with Comerica Bank, according to chairman & CEO Federico Pignatelli .
Lumenis says it hopes to bring in up to $106 million in its initial public offering, saying it will price shares in the $15 to $17 range.
Lumenis Ltd. said it plans to sell 6.25 million shares at $15 to $17 apiece in its upcoming initial public offering.
That would bring in between $93.8 million and $106.3 million for the Israeli medical laser maker, which announced the IPO late last year.
Biolitec AG appeals a Massachusetts federal judge's issuance of an arrest warrant for its CEO and a $63 million sanction in its legal war with AngioDynamics.